Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2009. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs), specifically detailing share-based awards granted on February 17, 2009, under the GlaxoSmithKline Share Option Plan.
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation details. Key compensation metrics include:
- Grant Date: February 17, 2009
- Exercise Price: £11.77 per Ordinary share (or US$33.42 per ADS)
- Market Price at Grant: £11.77 per Ordinary share (or US$33.42 per ADS)
- Share Structure: One ADS equals two Ordinary shares
Material Changes
The filing does not report material changes in financial performance or operations compared to prior periods. The primary change disclosed is the issuance of new share options to senior executives, subject to specific performance conditions tied to Earnings Per Share (EPS) growth relative to the Retail Prices Index (RPI).
Guidance, Outlook, and Risks
Performance Conditions: Vesting is contingent on GSK's compound annual EPS growth exceeding the RPI by specific margins over defined periods:
- Threshold: No options vest unless EPS growth exceeds RPI by 3% per annum.
- Vesting Schedule:
- 30% vest at 3% p.a. excess over RPI
- 65% vest at 4% p.a. excess over RPI
- 85% vest at 5% p.a. excess over RPI
- 100% vest at 6% p.a. or more excess over RPI
- Measurement Periods:
- 50% of options measured over three years (Jan 1, 2009 – Dec 31, 2011)
- 50% of options measured over four years (Jan 1, 2009 – Dec 31, 2012)
Risks and Contingencies: Options will lapse if the performance conditions are not met by the vesting dates (February 17, 2012, and February 17, 2013). The filing does not disclose other operational risks or contingencies.
Investor Verification Checklist
- Verify the total number of options granted to specific executives listed in the filing tables.
- Confirm the current EPS growth trajectory relative to the RPI to assess the likelihood of vesting.
- Review the full GlaxoSmithKline Share Option Plan terms for additional conditions not detailed in this summary.
- Check subsequent filings for updates on the vesting status of these awards in 2012 and 2013.